Head to Head Review: Everi (EVRI) versus Interpace Diagnostics Group (IDXG)

Everi (NYSE: EVRI) and Interpace Diagnostics Group (NASDAQ:IDXG) are both small-cap industrials companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Everi and Interpace Diagnostics Group, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Everi 0 0 3 0 3.00
Interpace Diagnostics Group 0 0 1 0 3.00

Everi presently has a consensus target price of $7.33, indicating a potential downside of 4.76%. Interpace Diagnostics Group has a consensus target price of $5.00, indicating a potential upside of 395.05%. Given Interpace Diagnostics Group’s higher possible upside, analysts plainly believe Interpace Diagnostics Group is more favorable than Everi.

Insider & Institutional Ownership

84.1% of Everi shares are owned by institutional investors. Comparatively, 6.1% of Interpace Diagnostics Group shares are owned by institutional investors. 4.5% of Everi shares are owned by company insiders. Comparatively, 0.7% of Interpace Diagnostics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Everi has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Interpace Diagnostics Group has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.

Valuation and Earnings

This table compares Everi and Interpace Diagnostics Group’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Everi $859.46 million 0.60 -$249.47 million ($3.69) -2.09
Interpace Diagnostics Group $13.09 million 2.07 -$8.33 million $3.02 0.33

Interpace Diagnostics Group has lower revenue, but higher earnings than Everi. Everi is trading at a lower price-to-earnings ratio than Interpace Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Everi and Interpace Diagnostics Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Everi -25.82% -16,159.62% -16.70%
Interpace Diagnostics Group -6.33% -5.69% -3.06%

Summary

Interpace Diagnostics Group beats Everi on 8 of the 12 factors compared between the two stocks.

Everi Company Profile

Everi Holdings Inc. is a holding company. The Company operates through subsidiaries, including Everi Games Holding Inc. (Everi Games Holding) and Everi Payments Inc. (Everi Payments or Payments). The Company operates through two segments: Games and Payments. The Company provides video and mechanical reel gaming content and technology solutions, integrated gaming payments solutions, and compliance and efficiency software. Its games segment provides solutions directly to gaming establishments to offer its patrons gaming entertainment related experiences. The Payments segment provides solutions directly to gaming establishments to offer their patrons cash access related services and products, including access to cash at gaming facilities through automatic teller machine (ATM) cash withdrawals, credit card cash access transactions and point of sale debit card transactions.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Receive News & Ratings for Everi Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Everi Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply